Canadian cardiovascular society and Canadian thoracic society position statement on pulmonary arterial hypertension

Canadian Journal of Cardiology

Volumn 21, Issue 11, 2005, Pages 909-914

  Langleben, David ^a,f   Archer, Stephen ^b   Granton, John ^c   Hirsch, Andrew M ^a   Levy, Robert D ^d   Mehta, Sanjay ^e   Michelakis, Evangelos ^b   Stewart, Duncan J ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Canadian health system; Endothelin; Nitric oxide; Prostaglandins; Pulmonary artery; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; AMLODIPINE; BIOLOGICAL MARKER; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ILOPROST; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V; PLACEBO; PROSTACYCLIN; SEROTONIN; SEROTONIN RECEPTOR; SILDENAFIL; SITAXSENTAN; THROMBOXANE A2; TROPONIN; UNINDEXED DRUG; UNIPROST; URIC ACID; WARFARIN;

ARTICLE; CANADA; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; EDEMA; ELECTROCARDIOGRAPHY; FLUSHING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; INFLAMMATION; INFUSION PUMP; INJECTION PAIN; INJECTION SITE REACTION; INTERNATIONAL CLASSIFICATION OF DISEASES; LIVER TOXICITY; MEDICAL EXPERT; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PATHOGENESIS; PHYSICAL EXAMINATION; PHYSICIAN; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RESOURCE MANAGEMENT; SEPSIS; THORAX RADIOGRAPHY; TREATMENT INDICATION;

CANADA; HUMANS; HYPERTENSION, PULMONARY; SOCIETIES, MEDICAL;

EID: 27744602269     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11:686-705.
2. Wood P, Besterman EM, Towers MK, McIlroy MB. The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J 1957;19:279-86.
3. Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med 2001;22:385-91.
4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl S):5S-12S.
5. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(Suppl S):40S-7S.
6. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-9.
7. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl S):25S-32S.
8. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-34.
9. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-11.
10. Weir EK, Reeve HL, Johnson G, Michelakis ED, Nelson DP, Archer SL. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest 1998;114(Suppl 3):200S-4S.
11. + channel gene transcription in primary pulmonary hypertension. Lancet 1998;351:726-7.
12. Voelkel NF, Cool CD, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998;114(Suppl 3):225S-30S.
13. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998;114(3 Suppl):213S-24S.
14. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
15. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
16. Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001;345:367-71.
17. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research "work in progress". Circulation 2000;102:2781-91.
18. Tuder RM, Cool CD, Geraci MW, et al. Prostacycline synthase gene expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
19. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
20. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991;114:464-9.
21. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
22. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S.
23. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
24. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;109:844-8.
25. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487-92.
26. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
27. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-4.
28. Groves BM, Badesch DB, Turkevitch D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K, ed. Ion Flux in Pulmonary Vascular Control. New York: Plenum Press, 1993:317-30.
29. Sitbon O, Humbert M, Jais X, et al. Acute vasodilator responsiveness and long-term response to calcium channel blockers in different forms of PAH. Am J Respir Crit Care Med 2004;169:A210. (Abst)
30. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
31. Barst RJ, Rubin LJ, McGoon MD, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
32. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
33. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
34. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
35. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
36. Fedullo PF, Auger WR, Channick RN, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 2001;22:561-81.
37. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
38. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 2003;124:247-54.
39. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):81S-88S.
40. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
41. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
42. Fuster VF, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-7.
43. Valentini V, Seiditz M, Dodin E, et al. Acute effects of digoxin on hemodynamics, neurohormones and baroreceptor response in pulmonary hypertension. Circulation 1996;94:I23-4. (Abst)
44. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
45. Rubin L, Galie N, Badesch D, et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:A210. (Abst)